close 74% van de retail beleggers lijdt verlies op de handel in CFD`s met deze aanbieder. Investeringen brengen risico`s met zich mee en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 74% van de retail beleggers lijdt verlies op de handel in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard

ASML

1,206.6

+2.57%↑

SAP

147.78

-3.53%↓

IFX

38.48

+0.47%↑

NOKIA.FI

7.04

+2.33%↑

STMPA.FR

27.51

+1.89%↑

ASML

1,206.6

+2.57%↑

SAP

147.78

-3.53%↓

IFX

38.48

+0.47%↑

NOKIA.FI

7.04

+2.33%↑

STMPA.FR

27.51

+1.89%↑

ASML

1,206.6

+2.57%↑

SAP

147.78

-3.53%↓

IFX

38.48

+0.47%↑

NOKIA.FI

7.04

+2.33%↑

STMPA.FR

27.51

+1.89%↑

ASML

1,206.6

+2.57%↑

SAP

147.78

-3.53%↓

IFX

38.48

+0.47%↑

NOKIA.FI

7.04

+2.33%↑

STMPA.FR

27.51

+1.89%↑

ASML

1,206.6

+2.57%↑

SAP

147.78

-3.53%↓

IFX

38.48

+0.47%↑

NOKIA.FI

7.04

+2.33%↑

STMPA.FR

27.51

+1.89%↑

Home・Aandelen Lijst・Kontron AG
Search

Kontron AG

Open

SectorTechnologie

18.92 -2.47

Buy

Prijsupdate 24 mrt 2026, 14:30 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

18.56

Max

19.52

Belangrijke statistieken

By Trading Economics

Inkomsten

-51M

22M

Verkoop

5.1M

401M

EPS

0.347

Dividendrendement

2.48

Winstmarge

5.461

EBITDA

-48M

51M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+46.91% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.48%

2.29%

Volgende Winsten

26 mrt 2026

Nieuwssentiment

By Acuity

13%

87%

19 / 376 Rangschikking in Technology

Kontron AG Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 mrt 2026, 23:47 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

DJ

Lezen

23 mrt 2026, 22:55 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

DJ

Lezen

23 mrt 2026, 21:51 UTC

Acquisities, Fusies, Overnames

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

DJ

Lezen

23 mrt 2026, 23:59 UTC

Marktinformatie

Global Equities Roundup: Market Talk

DJ

Lezen

23 mrt 2026, 23:59 UTC

Marktinformatie

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

DJ

Lezen

23 mrt 2026, 23:50 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

DJ

Lezen

23 mrt 2026, 23:37 UTC

Marktinformatie

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

DJ

Lezen

23 mrt 2026, 22:42 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Global Equities Roundup: Market Talk

DJ

Lezen

23 mrt 2026, 22:42 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

DJ

Lezen

23 mrt 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

DJ

Lezen

23 mrt 2026, 22:23 UTC

Marktinformatie

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

DJ

Lezen

23 mrt 2026, 22:22 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

DJ

Lezen

23 mrt 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

DJ

Lezen

23 mrt 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

DJ

Lezen

23 mrt 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

DJ

Lezen

23 mrt 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

DJ

Lezen

23 mrt 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

DJ

Lezen

23 mrt 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

DJ

Lezen

23 mrt 2026, 22:18 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

DJ

Lezen

23 mrt 2026, 22:15 UTC

Acquisities, Fusies, Overnames

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

DJ

Lezen

23 mrt 2026, 22:08 UTC

Marktinformatie

Ebos Needs to Reset Its Gearing Targets -- Market Talk

DJ

Lezen

23 mrt 2026, 21:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

DJ

Lezen

23 mrt 2026, 21:42 UTC

Marktinformatie

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

DJ

Lezen

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

DJ

Lezen

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

DJ

Lezen

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

DJ

Lezen

23 mrt 2026, 21:10 UTC

Belangrijke Nieuwsgebeurtenissen

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

DJ

Lezen

23 mrt 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

DJ

Lezen

23 mrt 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

DJ

Lezen

23 mrt 2026, 20:50 UTC

Marktinformatie
Winsten
Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

DJ

Lezen

Peer Vergelijking

Prijswijziging

Kontron AG Prognose

Koersdoel

By TipRanks

46.91% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 28.5 EUR  46.91%

Hoogste 30 EUR

Laagste 27 EUR

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kontron AG - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan Kontron AG - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

19 / 376 Rangschikking in Technologie

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Kontron AG

Kontron AG

Andere aandelen uit de sector

ASML

ASML Holding NV

1,206.6

↑ +2.57%

SAP

SAP SE

147.78

↓-3.53%

IFX

Infineon Technologies AG

38.48

↑ +0.47%

NOKIA.FI

Nokia Oyj

7.04

↑ +2.33%

STMPA.FR

STMicroelectronics NV

27.51

↑ +1.89%
help-icon Live chat